Ipsen, Skyhawk ink potential $1.8B deal to target RNA in neuro diseases
Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.